Literature DB >> 1848477

Low frequency of ras activation in 2-acetylaminofluorene- and 3'-methyl-4-(dimethylamino)azobenzene-induced rat hepatocellular carcinomas.

H Li1, G H Lee, J Liu, K Nomura, K Ohtake, T Kitagawa.   

Abstract

Activation of ras protooncogenes in 11 2-acetylaminofluorene (AAF)-induced hepatocellular carcinomas (HCCs) or liver cell lines and 9 3'-methyl-(dimethylamino)azobenzene (3'-Me-DAB)-induced HCCs in rats was examined using the NIH3T3 cell transfection assay and oligonucleotide hybridization analysis. Only one cell line established from a AAF-treated rat liver demonstrated transforming activity with a point mutation and ATTA transversion at the second position of H-ras codon 61. The rates of ras activation were thus very low for both AAF- and 3'-Me-DAB-induced rat HCCs, the results thus extending and confirming the findings indicating that ras activation in rat HCCs induced by various type of carcinogens is infrequent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848477     DOI: 10.1016/0304-3835(91)90188-n

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

Review 1.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  In vitro progression-associated c-H-ras activation in neoplastic hepatocyte lines established from SV40-T antigen gene-harboring transgenic mice.

Authors:  H Li; J Liu; K Nomura; G H Lee; O Hino; K Ohtake; S Aizawa; T Kitagawa
Journal:  Jpn J Cancer Res       Date:  1991-01

3.  Absence of ras family point mutations at codons 12, 13 and 61 in N-ethyl-N-hydroxyethylnitrosamine- or N-nitrosomorpholine-induced renal cell tumors in rats.

Authors:  K Matsumoto; H Tsuda; T Iwase; M Ito; Y Nishida; F Oyama; K Titani; T Ushijima; M Nagao; I Hirono
Journal:  Jpn J Cancer Res       Date:  1992-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.